It has been an eventful year for Lucira Health, the company that secured the very first Emergency Use Authorization (EUA) for an at-home COVID-19 test product back in November 2020. In February, the Lucira COVID-19 & Flu Home Test became the first at-home assay for detecting and differentiating between influenza A, influenza B, and SARS-CoV-2 to receive EUA clearance for over-the-counter (OTC) use.
The positive news was tempered by its occurrence just as flu season was ending. Having banked on an August approval date, the California-based diagnostics developer had to file for Chapter 11 bankruptcy protection just two days before announcement of the combo test approval.
On April 20, Lucira Health’s story took another major turn when Pfizer acquired it for $36.4 million in a bankruptcy auction.
For more laboratory business news, including more on the Lucira Health story, see our Laboratory Industry Report. Subscribe or sign up for a free trial for access.